Investigation on Advanced Non-Small-Cell Lung Cancer among Elderly Patients Treated with Chinese Herbal Medicine versus Chemotherapy: A Pooled Analysis of Individual Data

Table 3

Hazard ratio estimates based on stratified cox model.

	Univariate Analysis		Multivariate Analysis
	HR (95 CI)	p-value	HR (95 CI)	p-value
Gender
Male	1.00
Female	0.8117 (0.68, 1.)	0.261
Age (continuous)	1.00 (0.99, 1.02)	0.664
Age (categorical)
⩽70	1.00
>70	1.08 (0.86, 1.37)	0.491
Smoking Status
Non-smoker	1.00		1.00
Smokers	1.20 (0.96, 1.51)	0.112	1.15 (0.84, 1.46)	0.221
Tumor Location
Central Type	1.00
Peripheral Type	1.05 (0.81, 1.36)	0.726
Pathology
Non-SQCC	1.00
SQCC	1.09 (0.86, 1.38)	0.467
Stage
III	1.00		1.00
IV	1.13 (1.00, 1.28)	0.054	1.11 (0.97,1.26)	0.103
Previous Treatment
No	1.00
Yes	1.06 (0.82, 1.37)	0.671	1.03 (0.78, 1.34)	0.853
KPS
60	1.00		1.00
70	0.70 (0.46, 1.07)	0.096	0.74 (0.48, 1.14)	0.168
⩾80	0.36 (0.23, 0.56)	<0.001	0.39(0.25, 0.61)	<0.001
Treatment
Chemotherapy	1.00		1.00
CHM	0.97 (0.87, 1.09)	0.588	0.98 (0.87, 1.10)	0.751

SQCC, squamous cell carcinoma; KPS, Karnofsky performance scores; CHM, Chinese herbal medicine; HR, hazard ratio; CI, confidence intervals.